MERCK & CO, INC. for MERCK & CO INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2010 | $842,000 | Replaced |
| 2nd Quarter - Amendment | Jul 20, 2010 | $895,000 | Replaced |
| 2nd Quarter - Amendment | Jul 20, 2010 | $944,000 | Yes |
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260). Settlement of patent litigation (no specific bill).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
Medicare/Medicaid MMM
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| G LAWRENCE ATKINS | — |
| VICTORIA BLATTER | — |
| ERIN DARLING | — |
| ANNE ESPOSITO | — |
| JANE HORVATH | — |
| ELI JOSEPH | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Financial Institutions/Investments/Securities FIN
End-use of derivatives (H.R. 4173)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| JASON BENJAMIN VAN PELT | — |
Taxation/Internal Revenue Code TAX
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| JASON BENJAMIN VAN PELT | — |
Health Issues HCR
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| G LAWRENCE ATKINS | — |
| VICTORIA BLATTER | — |
| ERIN DARLING | — |
| ANNE ESPOSITO | — |
| JANE HORVATH | — |
| ELI JOSEPH | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Budget/Appropriations BUD
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| JASON BENJAMIN VAN PELT | — |
Chemicals/Chemical Industry CHM
Pharmaceuticals in the environment (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANE HORVATH | — |
| ELI JOSEPH | — |
Consumer Issues/Safety/Products CSP
Access to over-the-counter medications (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
Animals ANI
Use of antibiotics in animals (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| G LAWRENCE ATKINS | — |
| ELI JOSEPH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.